HIV/AIDS infection rates won't budge

Caitlin Wilson | | Health Exec | Supply Chain

All over the world, the rate of new HIV/AIDS infections has stayed mostly the same in the last 10 years, Nature reports. The info comes from a new analysis in the journal The Lancet, which looked at infection trends from about 1980 to 2015.

The data shows that deaths from HIV/AIDS has steadily declined from its peak around 2005 (possibly because about 40 percent of HIV/AIDS patients are now receiving antiviral drugs). But the number of new infections has stayed steady, at about 2.5 million new cases each year (down from its 1997 peak of about 3.3 million).

Check out Nature to see the visual breakdown of the worldwide infection and death trends, plus a note about foreign aid’s role in the epidemic. 

Global rate of new HIV infections hasn't fallen in a decade

Caitlin Wilson,

Senior Writer

As a Senior Writer at TriMed Media Group, Caitlin covers breaking news across several facets of the healthcare industry for all of TriMed's brands.

Related Content

FDA issues Class I recall on counterfeit infusion pump batteries
FDA issues alert on PCNL sheath safety after patient death
DOJ sues CVS over unlawful opioid prescriptions and reimbursement
Bipartisan bills in Congress would force insurance companies, PBMs to sell pharmacies
FDA recalls 233K bottles of antidepressants due to cancer risk
FDA issues Class I recall on insulin syringes due to risk of death

Around the web

Cardiovascular Business
FDA says years-long tirzepatide shortage is resolved, will give limited leeway to compounders

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

AI in Healthcare
From Capitol Hill to a hospital near you? 5 federal recommendations for healthcare AI policy

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Cardiovascular Business
Merck spends up to $2B to license new weight loss drug with potential heart benefits

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.